ProQR Therapeutics (PRQR) Competitors

$1.51 -0.08 (-5.03%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$1.54 +0.03 (+1.99%)

As of 03:59 AM Eastern

PRQR vs. CTMX, CYRX, ZVRA, CLYM, and CADL

Should you buy ProQR Therapeutics stock or one of its competitors? MarketBeat compares ProQR Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ProQR Therapeutics include CytomX Therapeutics (CTMX), CryoPort (CYRX), Zevra Therapeutics (ZVRA), Climb Bio (CLYM), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry.

How does ProQR Therapeutics compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

In the previous week, CytomX Therapeutics had 6 more articles in the media than ProQR Therapeutics. MarketBeat recorded 12 mentions for CytomX Therapeutics and 6 mentions for ProQR Therapeutics. CytomX Therapeutics' average media sentiment score of 0.82 beat ProQR Therapeutics' score of 0.46 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProQR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 6.6% of CytomX Therapeutics shares are held by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CytomX Therapeutics has a net margin of -166.40% compared to ProQR Therapeutics' net margin of -331.33%. CytomX Therapeutics' return on equity of -36.61% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

CytomX Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market.

CytomX Therapeutics currently has a consensus price target of $12.78, suggesting a potential upside of 265.08%. ProQR Therapeutics has a consensus price target of $7.25, suggesting a potential upside of 380.13%. Given ProQR Therapeutics' higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

CytomX Therapeutics has higher revenue and earnings than ProQR Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.82	-$17.37M	-$0.41	N/A
ProQR Therapeutics	$17.99M	8.84	-$47.73M	-$0.50	N/A

Summary

CytomX Therapeutics beats ProQR Therapeutics on 12 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to CryoPort?

CryoPort (NASDAQ:CYRX) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

CryoPort has a net margin of 41.57% compared to ProQR Therapeutics' net margin of -331.33%. CryoPort's return on equity of -7.92% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

CryoPort has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market.

92.9% of CryoPort shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 10.1% of CryoPort shares are held by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, ProQR Therapeutics had 5 more articles in the media than CryoPort. MarketBeat recorded 6 mentions for ProQR Therapeutics and 1 mentions for CryoPort. CryoPort's average media sentiment score of 0.71 beat ProQR Therapeutics' score of 0.46 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProQR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

CryoPort has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	3.81	$78.30M	$1.35	9.86
ProQR Therapeutics	$17.99M	8.84	-$47.73M	-$0.50	N/A

CryoPort presently has a consensus target price of $14.44, suggesting a potential upside of 8.47%. ProQR Therapeutics has a consensus target price of $7.25, suggesting a potential upside of 380.13%. Given ProQR Therapeutics' higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

CryoPort beats ProQR Therapeutics on 13 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to Zevra Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

ProQR Therapeutics has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

In the previous week, ProQR Therapeutics had 4 more articles in the media than Zevra Therapeutics. MarketBeat recorded 6 mentions for ProQR Therapeutics and 2 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.62 beat ProQR Therapeutics' score of 0.46 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

ProQR Therapeutics currently has a consensus target price of $7.25, indicating a potential upside of 380.13%. Zevra Therapeutics has a consensus target price of $23.33, indicating a potential upside of 123.71%. Given ProQR Therapeutics' higher possible upside, equities analysts clearly believe ProQR Therapeutics is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Zevra Therapeutics has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	8.84	-$47.73M	-$0.50	N/A
Zevra Therapeutics	$106.47M	5.79	$83.23M	$1.99	5.24

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zevra Therapeutics has a net margin of 101.58% compared to ProQR Therapeutics' net margin of -331.33%. Zevra Therapeutics' return on equity of 51.49% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Zevra Therapeutics	101.58%	51.49%	28.86%

Summary

Zevra Therapeutics beats ProQR Therapeutics on 12 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to Climb Bio?

ProQR Therapeutics (NASDAQ:PRQR) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Climb Bio had 11 more articles in the media than ProQR Therapeutics. MarketBeat recorded 17 mentions for Climb Bio and 6 mentions for ProQR Therapeutics. Climb Bio's average media sentiment score of 0.69 beat ProQR Therapeutics' score of 0.46 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ProQR Therapeutics has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	8.84	-$47.73M	-$0.50	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

ProQR Therapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market.

ProQR Therapeutics currently has a consensus target price of $7.25, indicating a potential upside of 380.13%. Climb Bio has a consensus target price of $20.30, indicating a potential upside of 105.47%. Given ProQR Therapeutics' higher possible upside, research analysts clearly believe ProQR Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08

Climb Bio has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Climb Bio's return on equity of -31.45% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Climb Bio	N/A	-31.45%	-30.39%

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Climb Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Climb Bio beats ProQR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Candel Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Candel Therapeutics' return on equity of -60.42% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

Candel Therapeutics has higher earnings, but lower revenue than ProQR Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
ProQR Therapeutics	$17.99M	8.84	-$47.73M	-$0.50	N/A

In the previous week, Candel Therapeutics had 6 more articles in the media than ProQR Therapeutics. MarketBeat recorded 12 mentions for Candel Therapeutics and 6 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 0.46 beat Candel Therapeutics' score of 0.06 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
ProQR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Candel Therapeutics has a beta of -0.59, indicating that its stock price is 159% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market.

Candel Therapeutics currently has a consensus price target of $18.00, indicating a potential upside of 127.85%. ProQR Therapeutics has a consensus price target of $7.25, indicating a potential upside of 380.13%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

ProQR Therapeutics beats Candel Therapeutics on 9 of the 14 factors compared between the two stocks.

Get ProQR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRQR vs. The Competition

Export

Metric	ProQR Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$167.52M	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.80%	5.30%
P/E Ratio	-3.02	18.13	20.63	25.23
Price / Sales	8.84	289.87	554.93	79.80
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	2.85	6.57	9.69	6.63
Net Income	-$47.73M	$24.35M	$3.56B	$335.59M
7 Day Performance	-5.63%	-2.53%	-1.63%	-1.20%
1 Month Performance	-24.12%	-3.55%	-2.59%	-1.16%
1 Year Performance	-11.70%	53.51%	30.08%	28.10%

ProQR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRQR ProQR Therapeutics	3.4242 of 5 stars	$1.51 -5.0%	$7.25 +380.1%	-6.8%	$167.52M	$17.99M	N/A	180	Earnings Report Analyst Downgrade
CTMX CytomX Therapeutics	3.1996 of 5 stars	$3.88 +0.5%	$12.78 +229.3%	+72.4%	$660.34M	$76.20M	N/A	170
CYRX CryoPort	3.2409 of 5 stars	$13.04 -1.0%	$14.44 +10.7%	+99.3%	$657.22M	$176.18M	9.66	1,186	Gap Down
ZVRA Zevra Therapeutics	3.9198 of 5 stars	$11.05 +2.3%	$23.33 +111.2%	+20.4%	$653.28M	$106.47M	5.55	20
CLYM Climb Bio	3.278 of 5 stars	$11.17 +0.4%	$20.30 +81.7%	+665.9%	$639.59M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRQR) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProQR Therapeutics (PRQR) Competitors

PRQR vs. CTMX, CYRX, ZVRA, CLYM, and CADL

How does ProQR Therapeutics compare to CytomX Therapeutics?

Summary

How does ProQR Therapeutics compare to CryoPort?

Summary

How does ProQR Therapeutics compare to Zevra Therapeutics?

Summary

How does ProQR Therapeutics compare to Climb Bio?

Summary

How does ProQR Therapeutics compare to Candel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProQR Therapeutics (PRQR) Competitors

PRQR vs. CTMX, CYRX, ZVRA, CLYM, and CADL

How does ProQR Therapeutics compare to CytomX Therapeutics?

Does the media favor CTMX or PRQR?

Do institutionals & insiders believe in CTMX or PRQR?

Is CTMX or PRQR more profitable?

Which has more volatility & risk, CTMX or PRQR?

Do analysts rate CTMX or PRQR?

Which has higher earnings and valuation, CTMX or PRQR?

Summary

How does ProQR Therapeutics compare to CryoPort?

Is CYRX or PRQR more profitable?

Which has more volatility & risk, CYRX or PRQR?

Do institutionals and insiders hold more shares of CYRX or PRQR?

Does the media refer more to CYRX or PRQR?

Which has better earnings & valuation, CYRX or PRQR?

Do analysts prefer CYRX or PRQR?

Summary

How does ProQR Therapeutics compare to Zevra Therapeutics?

Which has more volatility & risk, PRQR or ZVRA?

Does the media prefer PRQR or ZVRA?

Do analysts recommend PRQR or ZVRA?

Which has preferable earnings and valuation, PRQR or ZVRA?

Do institutionals & insiders have more ownership in PRQR or ZVRA?

Is PRQR or ZVRA more profitable?

Summary

How does ProQR Therapeutics compare to Climb Bio?

Does the media prefer PRQR or CLYM?

Which has preferable earnings & valuation, PRQR or CLYM?

Which has more risk & volatility, PRQR or CLYM?

Do analysts rate PRQR or CLYM?

Is PRQR or CLYM more profitable?

Do insiders and institutionals believe in PRQR or CLYM?

Summary

How does ProQR Therapeutics compare to Candel Therapeutics?

Is CADL or PRQR more profitable?

Which has preferable earnings and valuation, CADL or PRQR?

Does the media refer more to CADL or PRQR?

Do insiders and institutionals have more ownership in CADL or PRQR?

Which has more risk and volatility, CADL or PRQR?

Do analysts prefer CADL or PRQR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools